Denali Therapeutics Inc. (DNLI) Institutional Ownership

Ownership Summary

Denali Therapeutics Inc. (NASDAQ:DNLI) showed up in the 13F filings of 246 institutional investors as of December 2025.

• They owned 85.8% of outstanding stock in December 2025, up from 79.6% the prior quarter.
• Their total shares held in DNLI increased 14.59% quarter over quarter, and separately, investors owning Denali Therapeutics increased 9.82% from a year ago.
• Activity in DNLI broke down as 135 buyers, 69 sellers, and 42 unchanged among 246 total holders.
• Altogether, these fund groups held 148.02Mn shares in DNLI by December 2025, up by 18.84Mn shares quarter on quarter, and up 17.76Mn shares year over year.
• BlackRock, Inc. holds the largest position in DNLI at 13.03Mn shares as of December 31, 2025, or 7.56% of shares outstanding.
• The most significant purchases of DNLI for the quarter ending December 2025 came from VANGUARD CAPITAL MANAGEMENT LLC (6.15Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.12Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.46Mn), ADAR1 Capital Management, LLC (1.77Mn), Crestline Management, L.P. (1.61Mn).
• The largest sales of DNLI for the quarter ending December 2025 came from Goldman Sachs Group Inc (3.26Mn), FMR LLC (1.52Mn), Capital Research Global Investors (1.21Mn), ALLIANCEBERNSTEIN L.P. (664.32K), CITADEL ADVISORS LLC (597.73K).
• Business Quant data shows the 10 biggest positions in Denali Therapeutics as of December 2025 are held by BlackRock, Inc. (13.03Mn), BAILLIE GIFFORD & CO (12.07Mn), T. Rowe Price Investment Management, Inc. (8.52Mn), Temasek Holdings (Private) Ltd (7.01Mn), State Street Corp (6.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (6.15Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.12Mn), FMR LLC (4.58Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (4.43Mn), Crestline Management, L.P. (4.42Mn).